Ann: Opthea Reports Half Year Results and Business Updates, page-11

There is nothing I have seen to make me think topline will come any less than 4 letters across all comers given the juicing of the patient population.

MB has most of her working life in this molecule and by all accounts she is a very smart person even in a sector where being smart is mandatory entry criteria. Then you have Fred and a whole host of others who are seasons biotech leaders with specialisation in retina who are also on board. Will they be risking their reputations on something so risky that it’s 50/50 chance that topline will pass or fail? I think not.

As I said before - SP likely to drop further into the low 80s in March but this has nothing to do with chance of success or failure of the trial.

I am hoping to have enough cash to invest more later in March but fairly overloaded as is.